China's COVID-19 vaccine trial shows promising results

CNC
Added On May 23, 2020

China's COVID-19 vaccine trial, the first such vaccine to reach phase 1 clinical trial, has been found to be safe, well-tolerated, and able to generate an immune response against the novel coronavirus in humans. 

 
That's according to a study published online on Friday by medical journal The Lancet. 
 
The journal said the open-label trial in 108 healthy adults shows promising results after 28 days and the final results will be evaluated in six months. 
 
Further trials are needed to tell whether the immune response it elicits effectively protects against SARS-COV-2 infection. 
 
A professor who is responsible for the study said these results mark an important milestone. 
 
The professor said that the results show a promising vision for the development of COVID-19 vaccines, but there is still a long way from this vaccine being available to all.